JP2007519739A5 - - Google Patents

Download PDF

Info

Publication number
JP2007519739A5
JP2007519739A5 JP2006551478A JP2006551478A JP2007519739A5 JP 2007519739 A5 JP2007519739 A5 JP 2007519739A5 JP 2006551478 A JP2006551478 A JP 2006551478A JP 2006551478 A JP2006551478 A JP 2006551478A JP 2007519739 A5 JP2007519739 A5 JP 2007519739A5
Authority
JP
Japan
Prior art keywords
polypeptide
diabetes
antibody
treatment
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006551478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007519739A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/002609 external-priority patent/WO2005072385A2/en
Publication of JP2007519739A publication Critical patent/JP2007519739A/ja
Publication of JP2007519739A5 publication Critical patent/JP2007519739A5/ja
Pending legal-status Critical Current

Links

JP2006551478A 2004-01-27 2005-01-27 下垂体細胞アデニル酸シクラーゼ活性化ペプチド（ｐａｃａｐ）受容体（ｖｃａｐ２）アゴニストおよびそれらの製薬学的使用方法 Pending JP2007519739A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53955004P 2004-01-27 2004-01-27
US56649904P 2004-04-29 2004-04-29
PCT/US2005/002609 WO2005072385A2 (en) 2004-01-27 2005-01-27 Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use

Publications (2)

Publication Number Publication Date
JP2007519739A JP2007519739A (ja) 2007-07-19
JP2007519739A5 true JP2007519739A5 (https=) 2008-05-01

Family

ID=34830483

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006551478A Pending JP2007519739A (ja) 2004-01-27 2005-01-27 下垂体細胞アデニル酸シクラーゼ活性化ペプチド（ｐａｃａｐ）受容体（ｖｃａｐ２）アゴニストおよびそれらの製薬学的使用方法

Country Status (13)

Country Link
US (1) US20090143283A1 (https=)
EP (1) EP1713493A4 (https=)
JP (1) JP2007519739A (https=)
KR (1) KR20070009554A (https=)
AU (1) AU2005208911A1 (https=)
BR (1) BRPI0507177A (https=)
CA (1) CA2554475A1 (https=)
EC (1) ECSP066793A (https=)
IL (1) IL176705A0 (https=)
MA (1) MA28335A1 (https=)
NO (1) NO20063801L (https=)
RU (1) RU2006130691A (https=)
WO (1) WO2005072385A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2575101A1 (en) * 2004-06-12 2005-12-29 Bayer Pharmaceuticals Corporation Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use
CA2607273A1 (en) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
CN101296708B (zh) * 2005-10-26 2011-12-07 伊莱利利公司 选择性vpac2受体肽激动剂
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
US10899834B2 (en) 2015-04-16 2021-01-26 H. Lundbeck A/S Anti-PACAP antibodies
KR102444717B1 (ko) 2016-04-15 2022-09-16 하. 룬드벡 아크티에셀스카브 인간화 항-pacap 항체 및 그의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU656230B2 (en) * 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
CA2379604A1 (en) * 1999-09-28 2001-04-05 Bayer Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
WO2003068805A2 (en) * 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
PL377025A1 (pl) * 2002-07-12 2006-01-23 Bayer Pharmaceuticals Corporation Agoniści receptora peptydu aktywującego przysadkową cyklazę adenylową (PACAP) -VPAC2 i ich farmakologiczne sposoby zastosowania

Similar Documents

Publication Publication Date Title
Baetta et al. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences
US10603283B2 (en) Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
Gallwitz Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Hanefeld Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
Pal et al. MDR-and CYP3A4-mediated drug–drug interactions
KR101894228B1 (ko) 리나글립틴 및 임의로 ｓｇｌｔ２ 억제제를 포함하는 약제학적 조성물 및 이의 용도
KR102062824B1 (ko) 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도
RU2600440C2 (ru) Твердые композиции, содержащие агонист glp-1 и соль n-(2-гидроксибензоил)амино)каприловой кислоты
Kim et al. Pharmaceutical application and development of fixed-dose combination: dosage form review
Van Heiningen et al. Absorption, metabolism and excretion of a single oral dose of 14C-repaglinide during repaglinide multiple dosing
JP2006506969A5 (https=)
RS64643B1 (sr) Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline i lubrikant
KR20100093055A (ko) Ｇｌｐ-1에 의한 유해 효과의 예방 방법
KR20080040643A (ko) 의약의 병용 및 그 용도
KR20200013100A (ko) 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR20110040883A (ko) 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
KR20110115582A (ko) Ｄｐｐ－４ 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제
CN101588795A (zh) 包含中间快速溶解层的分层药物制剂
EA037712B1 (ru) Кардио- и нефропротективная противодиабетическая терапия
Lau et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function
US11266652B2 (en) Methods of treating subjects having diabetes with chronic kidney disease
JP2007519739A5 (https=)
Sridhar et al. Sustained-release vildagliptin 100 mg in type 2 diabetes mellitus: a review
Mohsen et al. Recent therapeutic targets in diabetic nephropathy
KR20170123704A (ko) 제2형 당뇨병 환자의 치료